LOGIN  |  REGISTER
Chimerix
C4 Therapeutics

embecta to Participate in Upcoming Investor Conferences

February 08, 2023 | Last Trade: US$19.13 0.39 2.08

PARSIPPANY, N.J., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today announced that management will participate in the following upcoming investor conferences:

2023 BTIG Medical Technology Conference

  • Management will host virtual investor meetings on Wednesday, February 15, 2023.

2023 JP Morgan Global High Yield and Leveraged Finance Conference

  • Management will host a presentation session on Monday, March 6, 2023, at 2:00 p.m. Eastern Time (ET) in Miami, FL.

2023 Oppenheimer 33rd Annual Healthcare Conference

  • Management will host a virtual presentation session on Tuesday, March 14, 2023, at 8:00 a.m. ET. Audio webcasts of the presentations will be accessible under the “News & Events” section of the Company's investor relations website at investors.embecta.com.

About embecta 
embecta is one of the largest pure-play diabetes care companies in the world, leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com.

CONTACTS 

Investors:
Pravesh Khandelwal
VP, Head of Investor Relations
551-264-6547
Contact IR

Media:
Christian Glazar
Sr. Director, Corporate Communications 
908-821-6922 
Contact Media Relations

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page